We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Repercussions from the failed Plavix settlement continue at Bristol-Myers Squibb (BMS), with the apparently forced departure of CEO Peter Dolan and Senior Vice President and General Counsel Richard Willard on the recommendation of a federal monitor.